Assessment of live plague vaccine candidates

Valentina A. Feodorova, Lidiya V. Sayapina, Vladimir L. Motin

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Since its creation in the early twentieth century, live plague vaccine EV has been successfully applied to millions of people without severe complications. This vaccine has been proven to elicit protection against both bubonic and pneumonic plague, and it is still in use in populations at risk mainly in the countries of the former Soviet Union. Despite extensive efforts in developing subunit vaccines, there is a reviving interest in creation of a precisely attenuated strain of Yersinia pestis superior to the EV that can serve as a live plague vaccine with improved characteristics. Here we summarize decades of experience of the Russian anti-plague research in developing a standard protocol for early-stage evaluation of safety and immunogenicity of live plague vaccines. This protocol allows step-by-step comparison of the novel test candidates with the EV vaccine by using subcutaneous immunization and bubonic plague infection models in two animal species, e.g., guinea pigs and mice.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Number of pages12
StatePublished - Apr 1 2016

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745


  • Animal model
  • Attenuation
  • Infectious disease
  • Live vaccine
  • Mutant
  • Plague
  • Protection
  • Vaccine candidate
  • Virulence
  • Yersinia pestis

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics


Dive into the research topics of 'Assessment of live plague vaccine candidates'. Together they form a unique fingerprint.

Cite this